Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.

Trial Profile

Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TOPARP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results of exploratory analysis presented at the 2017 Genitourinary Cancers Symposium
    • 28 Jan 2016 According to an AstraZeneca media release, olaparib [Lynparza] has been granted breakthrough therapy designation by the US FDA for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide). The breakthrough therapy designation was based on the results of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top